Robson Dossa
Dr. Robson Dossa leads the development of allogeneic CAR-iNKT cell therapies at Arovella Therapeutics. Dedicated to delivering innovative treatments for patients with limited options, he has guided multiple cell therapy programs into clinical trials for both hematologic and solid tumors. His work focuses on building robust manufacturing platforms and regulatory strategies to accelerate the translation of breakthrough science into transformative therapies.
Abstracts this author is presenting:
